FLT3 and acute myeloid leukemia: Since quizartinib monotherapy hardly decreased primary and secondary engraftment in these models, the authors indicate that SIRT1 inhibition enhances the efficacy of the TKI through targeting LSCs.149 Therefore, FLT3-ITD AML patients may benefit from SIRT1 inhibition in combination with TKI therapy.